( MENAFN - GlobeNewsWire - Nasdaq) Published open-access today in Nature Genetics,“High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm. SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. This proximity bias, discoverable through Recursion's proprietary biological dataset, could have many downstream impacts on the community's ability to make meaningful progress in our understanding and treatment of disease within both large scale datasets and small gene-specific work.
CRISPR-Cas9 is a revolutionary technology that can be used as“molecular scissors” to edit the human genome. Upon investigation of the massive datasets within the Recursion OS, Recursion identified large-scale structural changes to the genome – chromosomal truncations – caused by CRISPR-Cas9 editing. The Recursion team subsequently confirmed the widespread presence of this effect in several widely-used public data resources, and, using proprietary datasets and its full stack techbio platform, developed an.
